Genentech Expands Oregon Fill/Finish Site
Genentech plans to invest more than $125 million in an expansion of its fill/finish facility in Hillsboro, OR.
Genentech announced on March 26, 2015 that it would invest more than $125 million in an expansion of its fill/finish facility in Hillsboro, OR. The fill/finish facility, which opened in April 2010, is currently home to warehousing and distribution. An increased demand for sterile products in Genentech’s pipeline necessitated an expansion to include the capacity for manufacturing, the company reports.
"This investment in our sterile production operations will result in the addition of up to 100 new skilled manufacturing jobs in the greater Portland area over the next five years, potentially bringing the total number of Genentech jobs in Oregon to over 500," said Larry Sanders, general manager and vice president, Hillsboro Technical Operations, in a press release.
Source: Genentech
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
